Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/30/25
End: 12/31/31
Due: 12/31/32
Phase: N/A
Priority: Normal
Start: 06/30/25
End: 12/31/27
Due: 12/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer | NCT06849947 | Yeon Hee Park | user2@example.com | None | 2025-06-30 | 2031-12-31 | 2032-12-31 | - | - | 2025-07-14 |
| Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer | NCT06616987 | Yeon Hee Park | user2@example.com | None | 2025-06-30 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |